Genovis

Genovis FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Genovis (GENO.ST) as of Oct 17, 2026 is 129.53 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 109.46 % — a change of 18.34% (higher).

FCF Conversion

129.53 %

YoY

18.34%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Genovis is 2025 129.53 % . FCF Conversion Rate (FCF/EBITDA) of Genovis was 2024 109.46 % . It decreases by 18.34% higher compared to the previous year.

The Genovis FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
179.99 SEK
Jan 1, 2019
83.46 SEK
Jan 1, 2020
-258.71 SEK
Jan 1, 2021
167.20 SEK
Jan 1, 2022
-42.47 SEK
Jan 1, 2023
89.34 SEK
Jan 1, 2024
109.46 SEK
Jan 1, 2025
129.53 SEK
The Genovis FCF Conversion history
YEARFCF ConversionYoY
129.53 %+18.34%
109.46 %+22.52%
89.34 %-310.34%
-42.47 %-125.40%
167.20 %-164.63%
-258.71 %-409.99%
83.46 %-53.63%
179.99 %+41.40%
127.30 %+9.26%
116.51 %+30.27%
89.44 %-21.86%
114.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genovis Stock analysis

What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genovis stock

FCF Conversion Rate (FCF/EBITDA) of Genovis is 129.53 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Genovis changed from 109.46 % to 129.53 %, representing a 18.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Genovis since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Genovis with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genovis

All Key Metrics — Genovis